Breath test device and method
AssigneeExalenz Bioscience Ltd.
InventorsIlan Ben-Oren, Gil Guggenheim, Avraham Hershkowitz, Yaron Ilan
Life of this patent
Estimating the term…
Abstract
There is provided a method of evaluating a liver condition of a subject, the method includes computing a fluctuation parameter from a liver breath test based on at least one of a percentage dose recovery (PDR) curve and a delta over baseline (DOB) curve of an isotope labeled methacetin, or a salt or a derivative thereof, and evaluating at least one liver condition of the subject, based at least on the fluctuation parameter. There is provided herein a method of evaluating a liver condition of a subject, the method includes computing a hepatic impairment score based at least on a breath test related parameter and on a demographic parameter.
Claims10
A method for non-invasively evaluating portal hypertension in a subject, comprising:
- administering to a subject an isotope labeled methacetin or a salt or a derivative thereof comprising carbon-13, carbon-14, oxygen-18 or any combination thereof;
- continuously collecting and analyzing, using a CO2 sensor, changes in time of a level of a metabolic product of the labeled methacetin or the salt or the derivative thereof in multiple samples of the subject's breath;
- receiving, in real-time, data indicative of magnitude of metabolization, percentage dose recovery (PDR), and cumulative PDR (CPDR);
- deriving, from the data, PDR peak time, PDR height or physiological noise;
- evaluating, via a processor, the portal hypertension based on an analysis of the derived PDR peak time, PDR height or physiological noise;
- and
- outputting an indication of the evaluated portal hypertension in the subject.
A device for non-invasively evaluating portal hypertension, the device comprising:
- a CO2 sensor adapted to sense changes over time of an isotope level of a metabolic product of labeled methacetin or a salt or a derivative thereof in a breath of a subject having been administered isotope labelled methacetin or a salt or a derivative thereof comprising carbon-13, carbon-14, oxygen-18 or any combination thereof;
- and
- a processor configured to:
- receive, in real-time, data indicative of percentage dose recovery (PDR) and cumulative PDR (CPDR)
- derive, from the data, PDR peak time, PDR height or physiological noise;
- evaluate portal hypertension based on an analysis of a the derived PDR peak time, PDR height or physiological noise;
- and
- output an indication of the evaluated portal hypertension in the subject.
Dependencies are inferred from the claim text.